CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 8 enrolled
Drug / intervention
Glycine +1 moredrug
Likely dose
Glycine 0.4 gfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00291226
NCT00291226Phase 3Completed
CompareCT.gov

Glycine vs Placebo for the Schizophrenia Prodrome

Yale University·interventional·Posted Feb 13, 2006·Updated Apr 2, 2020

In Brief

A Phase 3 clinical trial evaluating Glycine and Placebo for Schizophrenia Prodrome. Completed, enrolled 8 participants across 1 site.

Detailed Summary

Glycine is a natural amino acid neurotransmitter that acts as a co-agonist at NMDA receptors in brain. We hypothesize that symptoms of the schizophrenia prodrome will improve with glycine to a greater degree than with placebo.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia Prodrome
CountriesUnited States
CollaboratorsGlytech, Inc, National Alliance for Research on Schizophrenia and Depression

Timeline

Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 13, 2006
Enrollment StartMar 1, 2006
Primary CompletionJul 1, 2009
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 20.4 years ago

Interventions

Glycinedrug

Glycine 0.4 g/kg bid

Placebodrug

Placebo